In 2019, the FDA expanded pembrolizumab to be used as first-line treatment in metastatic NSCLC for patients with PD‐L1 TPS ≥ 1% and no EGFR or ALK genomic aberrations (5). Here, CD274 is linked to non-small cell lung carcinoma.